A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT05085028 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1750

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer, Nonsmall Cell

Interventions

DRUG: Pembrolizumab 25 MG/ML [Keytruda]

Sponsor

Imperial College London

Collaborators

[object Object]
[object Object]
[object Object]